Nov 14 (Reuters) - Relmada Therapeutics Inc RLMD.O:
RELMADA THERAPEUTICS INITIATES PHASE 1 DOSING WITH REL-P11 FOR METABOLIC DISEASE
RELMADA THERAPEUTICS INC - PHASE 2A PROOF-OF-CONCEPT STUDY EXPECTED TO BEGIN IN H1 2025
Source text: ID:nGNX4sn4n2
Further company coverage: RLMD.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.